Anatara Lifesciences Ltd (ANR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has a cash flow conversion efficiency ratio of -2.561x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.37 Million ≈ $-971.13K USD) by net assets (AU$535.97K ≈ $379.23K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anatara Lifesciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Anatara Lifesciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Anatara Lifesciences Ltd for a breakdown of total debt and financial obligations.
Anatara Lifesciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anatara Lifesciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trufin PLC
LSE:TRU
|
0.203x |
|
Aptitude Software Group PLC
LSE:APTD
|
-0.016x |
|
Yangaroo Inc
V:YOO
|
0.540x |
|
ARWAY CORP.
F:E65
|
0.458x |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
0.889x |
|
BioSenic S.A.
BR:BIOS
|
0.059x |
|
Duke Royalty Ltd
LSE:DUKE
|
0.039x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Anatara Lifesciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Anatara Lifesciences Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ANR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$535.97K ≈ $379.23K |
AU$-2.27 Million ≈ $-1.61 Million |
-4.239x | -363.73% |
| 2024-06-30 | AU$1.36 Million ≈ $965.52K |
AU$-1.25 Million ≈ $-882.61K |
-0.914x | +62.57% |
| 2023-06-30 | AU$924.54K ≈ $654.17K |
AU$-2.26 Million ≈ $-1.60 Million |
-2.442x | -49.22% |
| 2022-06-30 | AU$1.36 Million ≈ $965.33K |
AU$-2.23 Million ≈ $-1.58 Million |
-1.637x | -198.86% |
| 2021-06-30 | AU$3.83 Million ≈ $2.71 Million |
AU$-2.10 Million ≈ $-1.48 Million |
-0.548x | +42.59% |
| 2020-06-30 | AU$2.86 Million ≈ $2.02 Million |
AU$-2.72 Million ≈ $-1.93 Million |
-0.954x | -152.17% |
| 2019-06-30 | AU$5.92 Million ≈ $4.19 Million |
AU$-2.24 Million ≈ $-1.58 Million |
-0.378x | +2.02% |
| 2018-06-30 | AU$8.59 Million ≈ $6.08 Million |
AU$-3.32 Million ≈ $-2.35 Million |
-0.386x | -61.22% |
| 2017-06-30 | AU$12.02 Million ≈ $8.51 Million |
AU$-2.88 Million ≈ $-2.04 Million |
-0.239x | -1050.92% |
| 2016-06-30 | AU$13.48 Million ≈ $9.53 Million |
AU$-280.37K ≈ $-198.38K |
-0.021x | +94.08% |
| 2015-06-30 | AU$5.48 Million ≈ $3.88 Million |
AU$-1.92 Million ≈ $-1.36 Million |
-0.351x | -296.93% |
| 2014-06-30 | AU$7.23 Million ≈ $5.11 Million |
AU$-639.27K ≈ $-452.32K |
-0.088x | -114.01% |
| 2013-06-30 | AU$-280.65K ≈ $-198.58K |
AU$-177.22K ≈ $-125.39K |
0.631x | -- |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more